EGRX — Eagle Pharmaceuticals Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $12.99m
- $67.83m
- $316.61m
U.S. RESEARCH ROUNDUP- Applied Blockchain, Cheniere Energy, Roblox
Eagle Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary
Brief: Eagle Pharmaceuticals Reports First Quarter 2022 Results
Eagle Pharmaceuticals Inc expected to post earnings of $3.88 a share - Earnings Preview
Brief: Eagle Pharmaceuticals Reaches Settlement Agreement With Hospira Related To Bendeka (Bendamustine Hydrochloride) Until January 17, 2028
Eagle Pharma rises on deal to acquire Acacia Pharma
Brief: Eagle Pharmaceuticals Says Acacia To Pay $1 Mln If It Withdraws Recommendation Or Intends To Recommend Competing Proposal
Brief: Eagle To Buy Acacia Pharma, Values Capital At 94.7 Mln Euros
Eagle Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary
Brief: Eagle Pharmaceuticals Reports Fourth Quarter And Full Year 2021 Results
Eagle Pharmaceuticals Inc expected to post earnings of 94 cents a share - Earnings Preview
Eagle Pharmaceuticals Inc expected to post earnings of 94 cents a share - Earnings Preview
Brief: Eagle Pharmaceuticals Announces Commercial Availability Of Pemfexy
Brief: Eagle Pharmaceuticals On Track To Support Submission Of New Drug Application In Q2 2022 For Landiolol
Brief: Eagle Pharmaceuticals Announces Commercial Availability Of Vasopressin
Brief: Eagle Pharmaceuticals Provides 2022 Business Update And Announces Launch Of Vasopressin
Brief: Eagle Pharmaceuticals Receives 180 Days Of Marketing Exclusivity For Recently Approved Vasopressin
U.S. FDA approves Eagle’s generic version of Endo blood pressure drug (updated)
Eagle Pharma rises after FDA approves generic to Endo's Vasostrict